低氧诱导因子1alpha和多形质母细胞瘤中的血管内皮生长因子:超越病理影响的系统综述
Dimitra P Vageli1,2, Panagiotis G Doukas3, Kerasia Goupou2
1Department of Surgery, Yale University, New Haven, CT 06510, USA.
Oncology research
|July 26, 2024
概括
缺氧诱导因子1-alpha (HIF-1α) 和血管内皮生长因子 (VEGF) 免疫类型是多种质母细胞瘤 (GBM) 预后的关键生物标志物. 它们的表达水平与瘤进展,治疗疗效和患者存活率相关.
科学领域:
- 神经瘤学神经瘤学
- 分子生物学分子生物学
- 生物标志物发现发现
背景情况:
- 多形质母细胞瘤 (GBM) 是一种具有不良预后的侵袭性脑瘤.
- 瘤缺氧,由缺氧诱导因子1-alpha (HIF-1α) 和血管内皮生长因子 (VEGF) 介导,驱动GBM的进展和血管生成.
- 确定可靠的生物标志物来确定GBM的预后和治疗反应至关重要.
研究的目的:
- 系统地审查HIF-1α/VEGF免疫类型作为GBM预后生物标志物的作用.
- 调查它们与其他预后标志物,临床数据和成像发现的相关性.
- 评估它们在预测GBM治疗疗效方面的有用性.
主要方法:
- 对Medline,Embase和Pubmed数据库的系统审查 (搜索完成于2024年4月16日).
- 包括基于HIF-1α/VEGF表达,其他生物标志物或临床/成像数据评估GBM预后的研究.
- 分析了50项涉及1319个GBM标本,细胞系和动物模型的研究.
主要成果:
- 增加的HIF-1α/VEGF表达与不良的预后和瘤性因素 (例如,miR-210-3p,AKT) 相相关.
- 减少HIF-1α/VEGF表达与良好的预后和特定的临床表现相关 (例如,性).
- HIF-1α/VEGF免疫类型可以帮助区分MRI-PET上的瘤进展与伪进展,并反映治疗疗效.
结论:
- HIF-1α/VEGF免疫类型作为GBM预后的有价值的生物标志物.
- 这些生物标志物可以预测治疗疗效和患者存活率.
- 进一步的研究可能会完善它们在GBM患者的临床决策中的应用.
更多相关视频
12:09A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics
Published on: June 16, 2013
11.5K
12:52Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
15.8K
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K